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Abstract
Background: Nerve growth factor (NGF) is known to induce inflammation and pain; however its role in opioid-induced
tolerance has not been studied. This study investigated the effects of an anti-NGF neutralizing antibody on the
development of tolerance following chronic morphine treatment in naïve rats.
Methods: Four groups of rats were used in this study; one treated with saline alone, one with 10 mg/kg of morphine,
one with 10 μg of anti-NGF and the other with 10 mg/kg of morphine + 10 μg of anti-NGF, twice per day for 5 days.
The route of treatment was subcutaneous (S.C.) for morphine and saline, and intraperitoneal (i.p.) for anti-NGF. Response
to a noxious thermal stimulus during the course of drug treatment was assessed (Hargreaves’ test). Further, the change
in the NGF levels in the lumbar spinal cord was measured by ELISA.
Results: Our results showed that repeated administration of morphine produced an apparent tolerance which was
significantly attenuated by co-administration of anti-NGF (P < 0.001). Additionally, the area under the curve (AUC) of the
analgesic effect produced by the combination of morphine and anti-NGF was significantly (P < 0.001) greater than for
saline controls and chronic morphine treated rats. Moreover, the level of NGF in the spinal cord of chronic morphine
treated rats was significantly higher (P < 0.05) than in both the saline control group and the group receiving
simultaneous administration of anti-NGF with morphine. These results indicate that anti-NGF has the potential to
attenuate morphine-induced tolerance behavior by attenuating the effects of NGF at the spinal level.
Conclusion: Taken together, our study strongly suggests that the NGF signaling system is a potential novel target for
treating opioid-induced tolerance.
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Background
Morphine is a widely used analgesic drug. However,
multiple preclinical and clinical studies have shown that
chronic administration of morphine is associated with the
development of tolerance [1]. Literature shows that
opioid-induced tolerance (OIT), defined as a decreased
analgesic response following repeated administration of
the drug, is a complex phenomenon involving multiple
behavioral and cellular adaptations including alterations in
a number of pharmacokinetic and pharmacodynamic
aspects [2]. Emerging studies have shown that chronic
morphine treatment causes release of several inflamma-
tory mediators such as interleukin-1β (IL-1β), interleukin-
6 (IL-6), Tumor necrosis factor-α (TNF-α), transforming
growth factor-β1 (TGF-β1) and nuclear factor-kappa B
(NF-kB) from both neuronal and non-neuronal cells.
These inflammatory mediators have been shown to be
involved in the development of tolerance [3].
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Nerve growth factor (NGF) is an essential molecule
required for the survival of sympathetic and small diam-
eter primary afferent sensory neurons [4]. NGF exerts its
biological actions through two receptors: tropomyosin
receptor kinase A (trkA) and p75 receptor. There are a
substantial number of studies demonstrating involve-
ment of NGF in both central and peripheral nociceptive
processing [5]. Elevated levels of NGF have been
reported at the peripheral site of injury, in the dorsal
root ganglia (DRG) and in the spinal cord of animals
with neuropathic pain or/and inflammatory pain [5, 6].
Additionally, sequestration of NGF with antibodies or
blockade of NGF receptors with specific inhibitors atten-
uates allodynia and hyperalgesia [7]. Further, exogenous
administration of NGF to healthy animals and human
subjects induces dose-dependent allodynia and hyper-
algesia [5]. However, the role of NGF in OIT has not
been studied. Therefore, we hypothesize that chronic
morphine treatment increases spinal cord NGF levels
and this contributes to the development of OIT (Fig. 1).
To test this hypothesis we used a morphine-induced
tolerance protocol on rats and examined the effects of
treatment with NGF neutralizing antibodies on pain
behavior and on NGF levels in the spinal cord.
Methods
Animals
Male Sprague—Dawley rats (300–320 g) were housed 2/
cage under standard conditions (12:12 h light: dark cycle
with ad libitum access to food and water). All studies were
approved by the U.S. Army Institute of Surgical Research
Institutional Animal Care and Use Committee and conform
to federal guidelines and guidelines of the International
Association for the Study of Pain. This study has been con-
ducted in compliance with the Animal Welfare Act, the
implementing Animal Welfare Regulations, and the princi-
ples of the Guide for the Care and Use of Laboratory
Animals. The animal facility is fully accredited by the Asso-
ciation for the Assessment and Accreditation of Laboratory
Animal Care, International (AAALAC, Intl.).
Drugs and treatments
Anti-NGF-β antibody (lyophilized powder, Sigma-Aldrich,
N8773) and morphine sulfate (Hospira Inc.) were dissolved
or diluted in sterile phosphate buffered saline to desired
concentrations. Four groups of rats (n = 6) were used for
this study. They were randomly assigned to receive the fol-
lowing treatments: subcutaneous (s.c.) injection of saline
(0.5 ml); morphine (10 mg/kg in 0.5 ml, s.c.) along with
intraperitoneal (i.p.) saline (0.5 ml); morphine (10 mg/kg in
0/5 ml, s.c) along with anti-NGF (10 μg in 0.5 ml, i.p.); or
anti-NGF (10 ug in 0.5 ml, i.p.). The i.p. saline or anti-NGF
was administered within 1–2 min after morphine adminis-
tration. Each regimen was administered twice daily for 5
consecutive days. The time of drug administration was be-
tween 9–10 a.m. and 5–6 p.m.
Assessment of thermal sensitivity
Assessment of response to a noxious thermal stimulus
(Hargreaves test) was performed using a plantar anal-
gesia instrument (Model 390; IITC Life Science,
Woodland Hills, CA, USA) [8]. Briefly, rats were accli-
matized to the behavioral assessment room for 30 min
and to the Plexiglas chamber, which was placed above
a heated (35 C) transparent glass surface for 30 min
before the assessment. The light beam was focused to
the mid-plantar surface of the hind paw. The time be-
tween the application of thermal stimuli and hind paw
withdrawal response was defined as the paw with-
drawal latency in sec (PWL). The intensity of the beam
was set to 40 % to produce baseline PWL of approxi-
mately 10 s in naïve rats. Three trials for each hind
paw, with an interval of 5 min, were averaged and for
data analysis the scores from both left and right paws
were combined to yield the mean PWL of each rat.
The percentage of maximum possible antinociceptive
effect (% MPAE) was calculated using the formula: %
MPAE = (Post-morphine treatment – Pre-morphine
treatment) / (20-pre-morphine treatment) × 100. The
area under the curve (AUC) of PWL plotted over time
was calculated using the trapezoid rule. Additionally,
the PWL before treatment (baseline) on each test day
(day 1, day 3 and day 5) was analyzed to observe
changes in baseline sensitivity to thermal stimuli
during the experimental period. The behavioral experi-
menters were blinded to the treatments.
Chronic morphine treatment 
Activates  and releases 
Spinal NGF 
NGF contributes to morphine-induced hyperalgesia 
Inhibition of hyperalgesia 
Anti-NGF
Fig. 1 We propose that chronic morphine treatment causes the
release of NGF in the spinal cord, which contributes to morphine-
induced tolerance. Treatment with a low dose of anti-NGF antibody
delays development of tolerance
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Enzyme-linked immunosorbent assay (ELISA)
Following the final behavioral testing on day 5, rats from
each experimental group were sacrificed by decapitation
and the spinal cord tissue from lumbar sections L4 to L6
was harvested and snap frozen in liquid nitrogen and
stored at −80 °C. Quantitative determination of NGF
content in tissue samples was performed by ELISA,
according to the manufacture’s instruction (Biosensis;
catalogue number BEK-2214). Briefly, after weighing,
tissue was re-suspended in approximately 100 μl extrac-
tion buffer per 10 mg tissue, homogenized for 8–10 min
and placed on ice for 30 min. The homogenate was then
centrifuged at 100,000 × g and 4 °C for 30 min and the
clear supernatant collected into clean tubes. The sample
was diluted (1:2) in incubation/neutralization buffer be-
fore loading into the wells of an ELISA plate. The NGF
protein concentration of the sample was calculated
based on a standard NGF concentration-absorbance
curve (OD 450 nm) and expressed as pg/mL of protein
(Biosensis; catalogue number BEK-2214).
Statistical analysis
GraphPad Prism 5 statistical software was used to
analyze the experimental data. All data were expressed
as mean ± SEM. The data obtained from behavioral and
ELISA experiments were analyzed using either one-way
analysis of variance (ANOVA) or repeated-measures
ANOVA (Two-Way ANOVA) followed by Bonferroni’s
post-hoc test to compare the difference among groups.
The statistical significance was set at a level of p < 0.05.
Results
The development of OIT and effects of anti-NGF treat-
ment on that process was measured using the nocicep-
tive thermal test. A total of 24 rats (n = 6/group) were
included in the study.
Repeated morphine treatment alters baseline sensitivity
to thermal stimuli
As shown in Table 1, before treatment, the baseline PWL
in all groups ranged from 8.1–9.6 s, and ANOVA showed
no significant differences between groups (P > 0.05). The
pre-treatment paw withdrawal latencies of Sal-Sal group
did not differ significantly between days of testing
(P > 0.05). In contrast, the pre-treatment PWL pro-
gressively decreased in rats from Mor-Sal, Mor + Anti-
NGF and Anti-NGF-Sal groups. However, the signifi-
cant difference was observed on day 5 compared to
corresponding day 1 baseline latency (P < 0.05). Add-
itionally, the rats that received Mor-Sal and Mor +
Anti-NGF showed significant reduction in before
treatment PWL on day 5 (P < 0.05) compared to both
Sal-Sal and Anti-NGF-Sal groups. This also indicates
that the greater reduction in the basal nociceptive
behaviors is due to chronic morphine treatments but
not because of frequent handling and behavioral test-
ing of animals during the experimental period as the
baseline values of PWL did not alter in Sal-Sal-treated
group.
Anti-NGF attenuated morphine-induced tolerance
A single injection of morphine or morphine + anti-NGF
significantly increased the % MPAE in comparison to
the saline-treated group (P < 0.001) (Fig. 2). Morphine
treatment alone resulted in a 97.12 % MPAE whereas
the effect of the morphine + anti-NGF combination pro-
duced 88.45 % MPAE. On day 1, there was no significant
difference in the effect between these two treatment
groups (P > 0.05). Rats receiving repeated morphine
administration had a considerably reduced pain thresh-
old by day 3 and this continued until day 5 of treatment,
indicating development of tolerance. These chronic mor-
phine treated rats showed a slightly lower % MPAE than
the saline control group on days 3 & 5, but the effect
was not statistically significant (P > 0.05). In contrast,
simultaneous administration of anti-NGF with morphine
increased the % MPAE on days 3 and 5, to 67.95 and
42.71, respectively. These % MPAEs were significantly
higher than for the chronic morphine and saline control
rats (P < 0.001), suggesting a potential effect of anti-NGF
in blocking chronic morphine-induced tolerance. The
anti-NGF effect on day 5 was approximately 25 % less
than on day 3. Treatment with anti-NGF alone did not
alter the paw withdrawal latency and the nociceptive
threshold was almost same as the saline control group.
However, on day 3 chronic morphine treated rats
showed a 20.94 % lower MPAE than anti-NGF alone
treated rats (P < 0.05).
As shown in Fig. 2b, when the analgesic activity of mor-
phine and morphine + anti-NGF was expressed as the
AUC for PWL plotted against time (AUC 0–120 h), the
value for the morphine treated group was 266 units higher
than for the saline-treated control group (P < 0.05), and
the value for the morphine + anti-NGF group was 732
Table 1 Chronic morphine treatment alters baseline thermal
sensitivity
Mean paw withdrawal latencies (sec)
Day 1 Day 3 Day 5
Sal-Sal 8.87 ± 0.48 7.708 ± 0.29 8.498 ± 0.32
Mor-Sal 9.518 ± 0.48 7.891 ± 0.44 6.326 ± 0.36 ** ###
Mor + Anti-NGF 8.166 ± 0.42 8.042 ± 0.61 5.709 ± 0.22 ** ###
Anti-NGF-Sal 9.631 ± 0.16 9.049 ± 0.22 8.326 ± 0.15 ***
Data are expressed as mean ± SEM, and refer to paw withdrawal latencies
prior to Saline-Saline, Morphine-Saline, Morphine + Anti-NGF or Anti-NGF-
Saline treatment on the day 1, day 3 and day 5. ** P < 0.01, *** P < 0.001 as
compared to day 1 pre-treatment (baseline) of each corresponding group. ###
P < 0.001 represents significant difference compared to day 5 of Sal-Sal group
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units higher than for the saline controls (P < 0.001) and
645 units more than for the anti-NGF alone treatment
group (P < 0.001).
Repeated administration of morphine increases spinal
cord NGF levels
As illustrated in Fig. 3, the NGF protein expression in the
lumbar region of the spinal cord (L4-L6) of chronic mor-
phine treated rats was significantly higher than in saline
treated rats (P < 0.001). Rats that received repeated admin-
istration of morphine + anti-NGF expressed significantly
lower NGF levels in comparison to chronic morphine
treated rats (P < 0.001) but with levels similar to the saline
control group (P > 0.05). Repeated administration of anti-
NGF alone resulted in significantly lower amounts of NGF
in comparison to the morphine alone group (P < 0.01),
and those levels were similar to saline control and the
morphine + anti-NGF treated group.
Discussion
Currently, morphine is extensively used as a potent
analgesic drug for many types of moderate to severe, acute
and chronic pain conditions. However, prolonged use of
morphine induces tolerance, thus reducing its clinical
utility [3, 9, 10]. OIT mechanisms are complex. In animal
models, a decrease in analgesic response to noxious stim-
uli following short- and/or long-term exposure to opioids
is characterized as tolerant behavior [11, 12]. In agreement
with these reports, we also demonstrated the development
of tolerance in naïve rats to thermal stimuli following
Fig. 2 Effects of anti-NGF antibody on the development of morphine-induced tolerance (OIT). a. Hind paw withdrawal latency to thermal stimulation
expressed as percentage of maximal possible effect (% MPAE) decreased in rats that received chronic morphine treatment (10 mg/kg, s.c.) on days 3
and 5. Co-administration of morphine with anti-NGF (10 μg, i.p.) significantly reduced the decreased withdrawal latency on days 3 and 5. Each data
point represents the mean ± S. E. M. of six rats per group. ***P < 0.001 compared with either Morphine-Saline group or Anti-NGF-Saline; ###P < 0.001
compared Saline-Saline group or Anti-NGF-Saline group; $ P < 0.05 compared to Morphine-Saline group. b. Area under the curve (AUC) from 0 to
120 h, *P < 0.01 compared to Saline-Saline group, ***P < 0.0001 compared to Saline-Saline or Anti-NGF-Saline and Morphine-Saline groups
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chronic administration of morphine. The analgesic effect
of morphine, as indicated by increased %MPAE (increased
PWL), was significantly reduced by day 3 and this effect
continued until the end of the experiment.
There is ample evidence demonstrating that anti-NGF
attenuates pain hypersensitivity in a wide variety of animal
pain models [4, 5, 8, 13, 14] and it was shown to be effect-
ive through multiple routes of administration: intraperito-
neal (i.p.), subcutaneous (s.c.), intrathecal and local
application at the site of injury [13–15]. Anti-NGF acts by
binding and neutralizing the action of NGF on nocicep-
tors. Until the present study, the effect of anti-NGF on
morphine-mediated tolerance had not been determined.
We demonstrate that simultaneous i.p. administration of a
low dose of anti-NGF can attenuate the decreased %
MPAE of morphine that develops after multiple morphine
administrations. However, the analgesic effect of morphine
was not fully restored and also there is a reduced attenu-
ation of tolerance on day 5 compared to day 3. It is
possible that, in addition to NGF, other neurotrophins
such as brain-derived neurotrophic factor (BDNF) and
neurotrophin-3 (NT-3) could also contribute to opioid
tolerance. NGF, BDNF and NT-3 all bind to the neurotro-
phin receptor p75 (p75 NTR) in addition to their cognate
tyrosine kinase receptors – TrkA, TrkB, and TrkC. Inter-
estingly, a recent study has shown attenuation of opioid
analgesic tolerance in p75NTR null mice [16]. Likewise,
upregulation of BDNF and NT-3 occurs in the brain
regions that are involved in opioid dependence and with-
drawal following repeated morphine treatment [17–19].
These studies support the likely role for BDNF and NT-3,
in addition to NGF, in opioid tolerance mechanisms.
Moreover, other mechanisms are expected to contribute
to opioid-induced tolerance, apart from those involving
neurotrophins. For example, previous studies have shown
that glutamate signaling through NMDA receptors [20],
glial cell activation [3], nitric oxide signaling [21] and
down-regulation of opioid receptor expression [22], fol-
lowing repeated opioid treatment all can greatly decrease
the pain threshold. Further, the AUC of the analgesic
effect of the morphine + anti-NGF combination was sig-
nificantly greater than for the morphine alone group and
for the saline controls, supporting the hypothesis that
NGF signaling mediates OIT. Additionally, anti-NGF
treatment alone had no effect on the nociceptive threshold
in naïve rats, indicating that the anti-hyperalgesic effect of
anti-NGF in morphine tolerant rats is likely due to
neutralizing the effects of elevated NGF, and not to some
other anti-nociceptive effect of anti-NGF.
It has been reported that morphine acts on neuronal
and glial cells to cause the release of a number of inflam-
matory mediators that are involved in the development of
OIT [3]. Our ELISA results show that chronic morphine
treatment also induces the release of NGF in the spinal
cord and excessive expression of NGF correlates with
decreased analgesic behavior in tolerant animals. Earlier
studies have shown that nerve injury, inflammation and
tissue injury elevates NGF levels at the site of injury,
dorsal root ganglia and spinal cord [14]; however, our data
for the first time shows a morphine-mediated increase of
NGF levels in a non-injured condition. It is also possible
that subcutaneous, chronic administration of morphine
could increase NGF at the peripheral sites, and that this
could contributes to tolerance. Similarly, intraperitoneal
injections of anti-NGF could also block NGF action at the
periphery, in addition to its effects at the spinal cord level.
However, this study only assessed the NGF levels in the
spinal cord in morphine tolerant rats. Additionally, NGF
mediated hyperalgesia has been attributed to inflamma-
tion, degranulation of mast cells, activation of sympathetic
nerve terminals and action on TrKA-expressing primary
sensory neurons [5, 7, 13, 14]. Further studies are needed
to determine whether similar mechanisms are responsible
for the effects of NGF signaling in mediating OIT.
There is a commonly held concern regarding side
effects of high dose antibodies as therapeutics. The
anti-NGF dose that we used in this study is relatively
low (10 μg/injection) compared to amounts used in
other antibody therapy studies [13, 23]. Even so, less
than this dose was shown to be effective in attenuat-
ing mechanical hyperalgesia in an inflammatory pain
and spinal cord injury models [15, 23]. We propose
that higher doses of anti-NGF could be needed to-
abrogate OIT or opioid-induced hypersensitivity in
Fig. 3 Chronic morphine treatment increases the levels of NGF
in the spinal cord as measured by ELISA (Fig. 3). The quantity of
NGF protein in the lumbar sections (L4-L6) of chronic morphine
treated group showed more than three-fold higher than either
saline alone or anti-NGF alone treated groups. Co-administration
of anti-NGF antibody significantly decreased the NGF content.
No significant difference among saline, Anti-NGF and morphine
+ anti-NGF-treated groups was observed. Data are expressed as
mean ± SEM. ** P < 0.001 compared to Saline-Saline group and
## P < 0.001compared to Morphine + anti-NGF group
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animal models and in the clinic. We also propose
that the route of administration will likely be an
important factor in effectiveness.
The present study showed that the development of
OIT can be attenuated by co-administration of a low
dose of anti-NGF, along with morphine. Moreover,
chronic morphine treatment caused increased expres-
sion of NGF in the lumbar (L4-L6) region of the spinal
cord and this was significantly reduced to near control
levels in the rats receiving repeated morphine + anti-
NGF. These results strongly suggest that NGF signaling
plays a role in morphine-induced reduction of analgesic
effects and that suppression of NGF action with a
neutralizing antibody reduces OIT. This reduction is the
result of a true attenuation of tolerance as anti-NGF
treatment alone did not alter the baseline levels of NGF.
Conclusions
Taken together, our study strongly suggests that a low
dose of anti-NGF neutralizing antibody can reduce OIT
by blocking the action of NGF (Fig. 1). The NGF signaling
system is a potential novel target for treating OIT.
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